Pregnancy biomarker profiles, methods and compositions related thereto
AssigneeYale University
InventorsGuillermo G. Mor, Donna Neale, Roberto Romero
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions related to biomarker profiles for each trimester of pregnancy. The present invention also provides methods for identifying patients at risk of developing a complication of pregnancy, such as preeclampsia. In further embodiments, the present invention relates to methods for the diagnosis of patients with preeclampsia.
Claims52
A method for determining or aiding in the determination that a pregnant woman is at risk of developing preeclampsia, comprising comparing the expression of one or more biomarkers in a blood sample from the pregnant woman to be assessed for risk of developing preeclampsia to a predetermined standard for each of the one or more biomarkers, wherein a significant difference in expression of the one or more biomarkers in the sample as compared to a predetermined standard of each of the one or more biomarkers indicates that the pregnant woman is at risk of developing preeclampsia, thereby determining or aiding in the determination that the pregnant woman is at risk of developing preeclampsia.
A kit comprising one or more reagents for detecting two or more biomarkers selected from the group consisting of:
- IFNg, I-309, GM-CSF, GDNF, GCP-2, Fraktalkine, Flt-3 Ligand, FGF-7, FGF-6, Eotaxin-3, Eotaxin-2, Eotaxin, EGF, CNTF, CK b 8-1, BMP-6, BMP-4, BLC, BDNF, ANG, MCP-1, LIGHT, Leptin, IL-7, IL-6, IL-5, IL-4, IL-3, IL-2, IL-1ra, IL-1b, IL-1a, IL-16, IL-15, IL-13, IL-10, IGF-1, IGFBP-4, IGFBP-2, IGFBP-1, TNFB, TNFA, TGF-B3, TGF-B1, TARC, SDF-1, SCF, RANTES, PDGF-BB, PARC,NT-3, NAP-2, MIP-3A, MIP-1D, MIG, MDC, M-CSF, MCP-4, MCP-3, MCP-2, Lymphotactin, I-TAC, IL-8, IL-6R, IL-1 Ra, IL-17, IL-12 P70, IL-12 P40, IL-11, IL-1R1, IL-1 R4/ST2, IGF-1SR, IGFBP-6, IGFBP-3, ICAM-3, ICAM-1, HGF, HCC-4, GRO-A, GRO, VEGF-D, VEGF, uPAR, TRAIL R4, TRAIL R3, Thrombopoietin, TIMP-2, TIMP-1, TECK, sTNF RI, sTNF RII, SGP130, PIGF, Oncostatin M, Steoprotegin, NT-4, MSP-A, MIP-3B, MIP-1B, MIP-1A, MIF, Fas, FasL, and tissue factor.
A method of identifying a compound useful to treat preeclampsia, comprising:
- (a) identifying a candidate compound which regulates the expression of one or more biomarkers selected from the group consisting of:
- Ang, Leptin, RANTES, PDGF, ICAM 1, VEGF, G-CSF, Fas, EGF, IGFBP 1, MCP 1, IL8, and FasL;
- and
- (b) determining whether such candidate compound is effective to treat preeclampsia,
- wherein if the candidate compound is effective to treat preeclampsia, a compound useful to treat preeclampsia is identified.
A method of identifying preeclampsia risk biomarkers, comprising:
- (a) identifying two or more biomarkers that are potentially associated with a risk of developing preeclampsia;
- (b) comparing the level of expression of the biomarkers identified in step (a) in a first population of pregnant women at risk of developing preeclampsia to the expression of said two or more biomarkers in pregnant women not at risk of developing preeclampsia;
- (c) selecting biomarkers exhibiting a significant difference in expression in the first population of pregnant women at risk of developing preeclampsia;
- (d) comparing the level of expression of the biomarkers identified in step (c) in a second population of pregnant women at risk of developing preeclampsia to the expression of the two or more biomarkers in pregnant women not at risk of developing preeclampsia;
- and
- (e) selecting biomarkers exhibiting a significant difference in expression in the second population of pregnant women at risk of developing preeclampsia,
- wherein the biomarkers identified in step (e) are preeclampsia risk biomarkers.
Dependencies are inferred from the claim text.